Hyperlipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
Tarek Nafee (talk | contribs) No edit summary |
Tarek Nafee (talk | contribs) |
||
Line 52: | Line 52: | ||
== Classification == | == Classification == | ||
{{familytree/start |summary=Hyperlipoproteinemia}} | |||
{{familytree | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | A01= '''Hyperlipoproteinemia/Hyperlipidemia'''}} | |||
{{familytree | | | | | |,|-|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | | | }} | |||
{{familytree | | | | | D01 | | | D02 | | D03 | | D04 | | D05 | | D01= '''Type I:'''<br> [[Familial hyperchylomicronemia]]| D02= '''Type II'''| D03= '''Type III:'''<br>[[Dysbetalipoproteinemia]]| D04= '''Type IV:'''<br>[[Primary hypertriglyceridemia]]<br>| D05= '''Type V:''' <br>[[Mixed hyperlipoproteinemia]]}} | |||
{{familytree | | | | | |!| | |,|-|^|-|.| | |}} | |||
{{familytree | | | | | |!| | E01 | | E02 | | E01= '''Type A:'''<br> [[Familial hypercholesterolemia]]| E02= '''Type B:'''<br> [[Familial combined hyperlipidemia]]}} | |||
{{familytree/end}} | |||
{{Lipopedia}} | {{Lipopedia}} | ||
==References== | |||
{{Reflist|2}} | |||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
{{WH}} | {{WH}} |
Revision as of 19:48, 8 November 2016
Hyperlipoproteinemia Microchapters |
ACC/AHA Guideline Recommendations |
Intensity of statin therapy in primary and secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Synopsis
Hyperlipoproteinemia | Synonyms | Problems | Labs description | Treatment |
---|---|---|---|---|
Type I | Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia | Decreased lipoprotein lipase (LPL) or altered ApoC2 | Elevated chylomicrons | Diet control |
Type IIa | Polygenic hypercholesterolaemia or familial hypercholesterolemia | LDL receptor deficiency | Elevated LDL only | Bile acid sequestrants, statins, niacin |
Type IIb | Combined hyperlipidemia | Decreased LDL receptor and increased ApoB | Elevated LDL, VLDL and triglycerides | Statins, niacin, gemfibrozil |
Type III | Familial Dysbetalipoproteinemia | Defect in ApoE synthesis | Increased IDL | Drug of choice: Gemfibrozil |
Type IV | Endogenous Hyperlipemia | Increased VLDL production and decreased elimination | Increased VLDL | Drug of choice: Niacin |
Type V | Familial Hypertriglyceridemia | Increased VLDL production and decreased LPL | Increased VLDL and chylomicrons | Niacin, gemfibrozil |
Classification
Hyperlipoproteinemia/Hyperlipidemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type I: Familial hyperchylomicronemia | Type II | Type III: Dysbetalipoproteinemia | Type IV: Primary hypertriglyceridemia | Type V: Mixed hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||
Type A: Familial hypercholesterolemia | Type B: Familial combined hyperlipidemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||